Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Weekly Ratings on May 17, 2018

May 17, 2018 - By Laura Small

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

In total 2 analysts cover Collegium Pharmaceutical (NASDAQ:COLL). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:COLL)’s analyst reports since November 29, 2017 according to StockzIntelligence Inc. On Thursday, December 7 the firm has “Buy” rating given by Piper Jaffray. On Thursday, December 14 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) earned “Buy” rating by Piper Jaffray. On Monday, February 12 the firm earned “Buy” rating by Piper Jaffray. On Wednesday, November 29 the rating was maintained by Piper Jaffray with “Buy”. In Sunday, February 11 report Jefferies maintained it with “Buy” rating and $32.0 target. On Tuesday, January 23 Piper Jaffray maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with “Buy” rating. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
14/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0 Maintain
07/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
29/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $19.0 Maintain

The stock increased 2.20% or $0.54 during the last trading session, touching $25.1.Collegium Pharmaceutical, Inc. has volume of 186,789 shares. Since May 17, 2017 COLL has risen 133.98% and is uptrending. COLL outperformed by 122.43% the S&P500.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is valued at $829.40 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Currently it has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news posted recently go to: Benzinga.com, Seekingalpha.com, Globenewswire.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” posted on May 09, 2018, “FDA OKs first non-opioid treatment for opioid withdrawal” on May 16, 2018, “Collegium to Present at the Deutsche Bank Health Care Conference” with a publish date: May 02, 2018, “Collegium Reports First Quarter Financial Results and Provides Corporate Update” and the last “Collegium Pharmaceutical’s (COLL) CEO Michael Heffernan on Q1 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.